Adagene (ADAG) vs Cue Biopharma (CUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adagene (ADAG) has outperformed Cue Biopharma (CUE) over the past year, gaining 42.2% versus a loss of 13.2%. Over five years, ADAG leads with a -76.2% price change compared with -94.1% for CUE. Cue Biopharma is the larger company by market cap ($200.7 million vs $176.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | CUE |
|---|---|---|
| Share price | $2.63 | $27.63 |
| Market cap | $176.59M | $200.68M |
| 1-day change | -5.40% | +23.71% |
| YTD return | +47.09% | +144.04% |
| 1-year return | +42.20% | -13.25% |
| 5-year return | -76.24% | -94.09% |
| EPS (TTM) | $-0.37 | $-29.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $45.50 |
| 52-week low | $1.30 | $4.98 |
| Distance from 52-week high | -45.77% | -39.29% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +276.81% | +218.55% |
| Average volume | 244.76K | 267.15K |
| Shares outstanding | 67.14M | 7.26M |
| Employees | 128 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed CUE by 55.4 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
ADAG vs CUE FAQ
Which is bigger, Adagene or Cue Biopharma?
Cue Biopharma (CUE) is larger, with a market capitalization of $200.68M compared with $176.59M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or CUE?
ADAG returned +42.20% over the past 12 months, compared with -13.25% for CUE (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Cue Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.